Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 42.9%GRADE not reported 0 · 0%Very low 0 · 0%Low 4 · 57.1%Moderate 0 · 0%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide · Functional ability – HAQ‐DI Scale 0–3 with 0 representing no/mild impairment and 3 representing very severe impairment. The study incorporated a ≥ 0.4 threshold
  Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
Direct match · question page
- Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide · Skin thickness – mRSS Scale 0–51 in which a higher number is worse skin thickening
  Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 19 participants
  Low
Direct match · question page
- Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide · Overall mortality
  Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 19 participants
  Low
Direct match · question page
- Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide · Interstitial lung disease – FVC % predicted A lower percentage represents worse lung disease. The study incorporated a ≥ 15% chance
  Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 19 participants
  Low
Related · question page
- Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide · Event‐free survival
  Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide

Overall mortality · people with systemic sclerosis

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Low

Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide

Event‐free survival · people with systemic sclerosis

The review found no eligible studies for this question.

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide

Functional ability · people with systemic sclerosis

The review found no eligible studies for this question.

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide

Skin thickness – mRSS Scale 0–51 in which a higher number is worse skin thickening · people with systemic sclerosis

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Low

Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide

Interstitial lung disease – FVC % predicted A lower percentage represents worse lung disease. The study incorporated a ≥ 15% chance · people with systemic sclerosis

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Low

Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide

Pulmonary arterial hypertension · people with systemic sclerosis

The review found no eligible studies for this question.

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Autologous non‐myeloablative non‐selective HSCT vs cyclophosphamide

Serious adverse events · people with systemic sclerosis

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Low